GO
Loading...

Enter multiple symbols separated by commas

Dendreon Corp

  • LONDON, March 4- The idea of using vaccines to fight cancer has received a shot in the arm from a $1 billion deal between Bristol-Myers Squibb and Bavarian Nordic. Unfortunately, they have run into problems in practice, leading to a series of failures with experimental products such as Merck KGaA's Stimuvax and GlaxoSmithKline's MAGE-A3. The idea of combining...

  • NEW YORK, Feb 20- Valeant Pharmaceuticals International Inc is close to a deal to acquire bowel drug maker Salix Pharmaceuticals Ltd for around $160 per share, according to a person directly familiar with the matter. A deal of that size would be the largest ever for Valeant, which lost a takeover contest for Allergan Inc last year. The usually acquisitive Valeant...

  • Feb 10- Valeant Pharmaceuticals International Inc will scoop up bankrupt cancer vaccine maker Dendreon Corp, after no additional qualified bids came forward by Tuesday's deadline, Valeant said. Valeant, of Laval, Quebec, will get Seattle- based Dendreon's Provenge cancer treatment and other assets for $400 million in cash. Dendreon and Valeant will seek court...

  • Feb 10- Valeant Pharmaceuticals International Inc appears poised to scoop up bankrupt cancer vaccine maker Dendreon Corp after another potential buyer dropped from the bidding process, three sources close to the sale told Reuters. Valeant, of Laval, Quebec, has agreed to pay $400 million for the assets of Seattle- based Dendreon, best known for its Provenge...

  • Valeant, of Laval, Quebec, has agreed to pay $400 million for the assets of Seattle- based Dendreon, best known for its Provenge cancer treatment.

  • Jan 29- Bankrupt drugmaker Dendreon Corp has reached a stalking-horse deal with Canada's Valeant Pharmaceuticals International Inc to sell the worldwide rights to its cancer vaccine, Provenge, and certain assets for $296 million. The deal is subject to higher and better bids and extended the bid deadline to Feb. 10 for interested parties to participate in an...

  • Valeant to buy worldwide rights to Dendreon's Provenge Thursday, 29 Jan 2015 | 9:29 PM ET

    Jan 29- Valeant Pharmaceuticals International Inc said it would buy the worldwide rights of Dendreon Corp's Provenge drug and certain other assets through a "stalking horse" deal for $296 million. Seattle- based Dendreon filed for bankruptcy protection in November, after sales of its cancer vaccine fell short of expectations and left the company deep in debt.

  • Dendreon files for bankruptcy   Tuesday, 11 Nov 2014 | 11:00 AM ET
    Dendreon files for bankruptcy

    What led Dendreon, the company that pioneered a drug many considered the next big thing in cancer research, to file for bankruptcy?

  • S&P, Dow again rise to record closes amid earnings Monday, 10 Nov 2014 | 4:21 PM ET
    A trader works on the floor of the New York Stock Exchange, Oct. 15, 2014.

    Stocks edged higher on Monday as investors tracked corporate results as the earnings season starts to wind down.

  • Passive investing dangers   Monday, 10 Nov 2014 | 2:25 PM ET
    Passive investing dangers

    Is there a lesson to be learned from Dendreon's bankruptcy protection filing? CNBC contributor Herb Greenberg, provides perspective on the risks associated with passive investing.

  • Lots of risk in biotech: Pro   Monday, 10 Nov 2014 | 2:22 PM ET
    Lots of risk in biotech: Pro

    Discussing warning signs from Dendreon, and other worrisome companies, with Les Funtleyder, E Square Asset Management.

  • Dendreon declares bankruptcy   Monday, 10 Nov 2014 | 2:18 PM ET
    Dendreon declares bankruptcy

    Joseph Pantginis, Roth Capital, has been negative on Dendreon for a long time, ahead of the drugmaker's bankruptcy protection filing.

  • Early Movers: RIG, GOGO, PFE, GM, TWX & more Monday, 10 Nov 2014 | 7:53 AM ET
    A trader works on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Medicare agency focus of insider trading probes Wednesday, 29 Oct 2014 | 11:00 AM ET
    Department of Health and Human Services building, Washington.

    Federal authorities are investigating whether officials at the agency that runs Medicare leaked information that landed with Wall Street traders.

  • Midday Movers: Kate Spade, Chevron, Insys & more Tuesday, 12 Aug 2014 | 12:33 PM ET
    Traders work on the floor of the New York Stock Exchange in New York.

    Take a look at some of Tuesday's midday movers:

  • Early movers: BEAV, KORS, S, FB, SNE, TWX & more Tuesday, 10 Jun 2014 | 7:49 AM ET
    Traders on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Believe in strong Europe reimbursement: Dendreon CEO

    Biotech firm Dendreon is set to begin selling its prostate cancer vaccine "Provenge" in Europe. John Johnson, Dendreon chairman & CEO, discusses the European launch and addresses investor concerns.

  • Inside Ukraine's presidential pad and 'Ask Warren' Thursday, 27 Feb 2014 | 11:34 AM ET
    CNBC visits the palace of ousted Ukrainian President Viktor Yanukovych.

    This week on Talking Squawk: Tour some lavish digs, find out how you can ask Warren Buffett a question and get stock picks.

  • Midday stock movers: Netflix, Twitter, Express & More Monday, 13 Jan 2014 | 12:57 PM ET

    Some of Monday's midday movers:

  • Early movers: MRK, BKW, LORL, JPM, FB, BBRY & more Monday, 28 Oct 2013 | 7:35 AM ET

    Some of the names on the move ahead of the open.